Stay Ahead of the Game With Prestige Consumer Healthcare (PBH) Q1 Earnings: Wall Street's Insights on Key Metrics

Wall Street analysts project Prestige Consumer Healthcare (PBH) to report Q1 earnings of $1.01 per share, a 12.2% year-over-year increase, on revenues of $261.91 million, representing a 2% decline. The consensus EPS estimate has remained unchanged over the last 30 days. While international OTC revenue is expected to see slight growth, North American OTC revenue is forecast to decline by 3.1%. PBH shares have underperformed the broader market, down 5.8% over the past month, and the stock carries a Zacks Rank #4 (Sell), indicating expectations for near-term underperformance.

Analysis

Prestige Consumer Healthcare (PBH) presents a mixed financial outlook ahead of its Q1 earnings report. Wall Street analysts forecast a 12.2% year-over-year increase in earnings per share to $1.01, suggesting potential margin improvement or effective cost management. However, this profitability growth is set against a projected 2% decline in total revenue to $261.91 million. The revenue weakness is primarily concentrated in the company's largest segment, North American OTC Healthcare, which is expected to contract by 3.1%. In contrast, the smaller International OTC Healthcare segment is anticipated to post modest revenue growth of 0.5%. This geographic divergence is also reflected in gross profit estimates, with North America seeing a slight decline while International posts a small gain. Despite the stable consensus EPS estimate over the past 30 days, the market has adopted a bearish view, with PBH shares underperforming the S&P 500 by over 6 percentage points in the last month (-5.8% vs +0.5%). This negative sentiment is underscored by a Zacks Rank #4 (Sell), suggesting expectations for near-term market underperformance.

Key Decisions for Investors

• Investors should scrutinize the upcoming earnings release to understand the drivers behind the forecasted 12.2% EPS growth in the face of a 2% revenue decline, focusing specifically on margin expansion and cost controls.
• The projected 3.1% revenue contraction in the core North American OTC segment is a significant headwind, and any guidance on the outlook for this market will be a critical determinant of future stock performance.
• Considering the stock's recent -5.8% underperformance and the explicit Zacks Rank #4 (Sell), a cautious approach is prudent as negative expectations are already partially priced in, but a revenue miss could lead to further downside.